|View printer-friendly version|
|‘Gene for speed’ researcher awarded Ramaciotti Medal|
Professor Kathryn North AM, the researcher responsible for discovering the ‘gene for speed’, has been awarded the prestigious Ramaciotti Medal for Excellence in Biomedical Research and a $50,000 grant.
Professor North is the Douglas Burrows Professor of Paediatrics and Child Health at the University of Sydney and Head of the Institute for Neuroscience and Muscle Research at the Children’s Hospital, Westmead. She will be presented with the medal at the annual Ramaciotti Awards tonight in Brisbane, where Perpetual will distribute over $1.6 million in funding to Australian biomedical researchers on behalf of the Ramaciotti Foundations. In February 2013, Professor North will become the Director of the Murdoch Children's Research Institute.
The Ramaciotti Medal recognises Professor North’s outstanding contribution to biomedical research in three key areas: neuromuscular disorders, neurofibromatosis, and the study of genes that influence athletic performance.
Professor North received worldwide recognition for leading the team that discovered a skeletal muscle gene (ACTN3) linked to athletic muscle performance and function, dubbed ‘the gene for speed’. Professor North’s research showed that although one in five Australians are deficient in α-actinin-3, no Olympic sprint athletes have ever been found deficient in the gene.
Professor North hopes to use the discovery to unlock new neuromuscular genetic information, which will help children and adults prevent, isolate or better manage muscular diseases in the future.
Professor North said, “Discovering the link between genetic variation and athletic performance opened a new path of study for both sports science and public health. Together with my research team, I’m now exploring how ACTN3 affects how individuals gain weight and respond to exercise. This is likely to emerge as an important risk factor for diabetes and obesity,” she said.
A large part of Professor North’s work is focused on understanding neuromuscular disorders such as muscular dystrophy. Leading a multi-disciplinary research team of more than 50, Professor North cares for over 900 children with a range of neuromuscular disorders - muscular dystrophy, myopathy and neuropathies - and over 1,200 children with Neurofibromatosis type 1.
“Our research team has a direct focus on health outcomes for children and adults with incurable disorders. We undertake much of this research in a clinical setting, where results can be promptly translated into improved health care. This means we have a significant impact on improving the lives of people suffering from neuromuscular disorders,” Professor North said.
She explains that neuromuscular disorders constitute one of the major causes of ongoing disability in childhood, and often cause early death from respiratory failure.
“Sadly, there is no cure for muscular dystrophies, but our work in the Institute for Neuroscience and Muscle Research has increased understanding of these diseases and improved the treatments that are available,” Professor North said.
The Ramaciotti Medal carries an award of $50,000 and recognises an outstanding contribution to clinical or biomedical research, or the way in which healthcare is delivered. The nominee must still be actively engaged in research. High profile past winners include Professor Sam Berkovic, Professor Chris Parish, Professor T J Martin, Professor Robert Baxter, Professor Ian Frazer, Professor Christopher Goodnow and Professor Michael Parker.
Andrew Thomas, General Manager, Philanthropy at Perpetual, which manages the Ramaciotti Foundations said, “The scope of Professor North’s research is truly impressive. It has improved the lives of those with neuromuscular diseases, led to breakthroughs in gene discovery, increased our understanding of athletic performance and created new ways to think about obesity and diabetes.
“What really stands out in Professor North’s body of work is her dedication to translating laboratory research into clinical practices that positively impact the lives of her patients,” he said.
Perpetual said the Ramaciotti Medal is an important way to recognise the contribution of Australia’s world-leading biomedical researchers.
“Australia’s biomedical researchers do extraordinary work, every day, to improve the health and lives of everyone in the community. The Ramaciotti Awards are an important opportunity to recognise some of the best work in the sector, and to provide funding to make it possible,” Mr Thomas said.
The Ramaciotti Foundations were established in 1970 with $6.7 million in funds. Since then, the charitable trusts have donated more than $52.5 million to biomedical research.
Enquiries please contact:
About the Ramaciotti Foundations
Since then, the Foundations have donated more than $52.5 million to biomedical research and are one of the largest contributors to the field. Their combined capital now stands at over $48 million.
The Ramaciotti Foundations continue to support biomedical research and each year make significant distributions via the Ramaciotti Awards, providing funding support to areas such as molecular biology, genetics and immunology, and assisting young investigators taking up new challenges in biomedical research.
At the 2012 Ramaciotti Awards, the Ramaciotti Foundations will grant over $1.6 million to biomedical research in Australia.
For more information about the Ramaciotti Foundations visit www.perpetual.com.au/ramaciotti
About the Ramaciotti Medal for Excellence in Biomedical Research
About the Ramaciotti Establishment and Equipment Grants
About the Ramaciotti Biomedical Research Award
About Perpetual Philanthropic Services
Perpetual Philanthropic Services is part of Perpetual Private, which advises clients on over $8 billion of funds (as at 30 June 2012). The Perpetual Private team of experts offer tailored advice and services and can help clients fulfill their charitable intentions. For more information visit www.perpetual.com.au/philanthropy.
Perpetual’s Philanthropic Services and advice are provided by Perpetual Trustee Company Limited (PTCo), ABN 42 000 001 007, AFSL 236643. This publication has been prepared by PTCo and contains information contributed by third parties. It contains general information only and is not intended to provide advice or take into account personal objectives, financial situation or needs. The information is believed to be accurate at the time of compilation and is provided by PTCo in good faith. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. PTCo does not warrant the accuracy or completeness of any information included in this document which was contributed by a third party.
|"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Perpetual - Media's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.|